Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Valeant grabs a Middle Eastern foothold with $800M pact for Egypt’s Amoun

July 20, 2015
Life sciences
Last month, reports said Valeant was stepping up talks on a deal for one of Egypt’s largest drugmakers. And now, it’s pulled the trigger.
 
The serial buyer has agreed to shell out $800 million on Amoun Pharmaceutical–plus contingent payments, it said in a statement. With that, it’ll grab the leading position in Egypt’s domestic pharma market and gain access to brands in the antihypertensive, broad-spectrum antibiotic and antidiarrheal spaces. Amoun is expecting to hit $223.5 million in sales this year and record a top-line swell of about 20%.
 
But Valeant isn’t expecting to keep its new business confined to Egypt. Rather, the Canadian pharma intends for Amoun to “serve as a platform for further expansion” in the Middle East and North Africa, emerging markets that CEO J. Michael Pearson likes for their speedy growth.
 
Beefing up in developing nations has been on Pearson’s agenda for a while now; it was one perk of the proposed Allergan ($AGN) merger, which Actavis eventually spoiled with a white knight swoop-in late last year. Since then, Valeant has made a pair of other acquisitions, though those–a buyout of North Carolina’s Salix and a pickup of bankrupt Dendreon’s assets–focused on different fast-expanding fields (GI and oncology, respectively).
 
Another burgeoning area Valeant’s long had on its radar? Animal health. Last month, sources told The Wall Street Journal it had approached market leader Zoetis, a company in which former deal partner Bill Ackman’s Pershing Square Capital Management holds a stake.
 
By Carly Helfand
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach